Early Phase Medical Affairs Strategic Planning

On-Demand Content | Virtual Event

Early Phase Medical Affairs Strategic Planning

Medical Affairs can gather insights to identify clinically meaningful differentiators by engaging with the external community years ahead of launch. These insights can inform clinical strategy and a holistic evidence generation plan that will produce and enhance value substantiation. As the product progresses through its development cycle, the evidence generation priorities and opportunities of the product will evolve. At the prelaunch phase, generating registration data will be prioritized, whereas during launch, generating real world and economic evidence will become more prominent.

SPEAKER HIGHLIGHTS

Liliana Alfaya-Virzi
Liliana Alfaya-Virzi
Med Director, IO

CELLECTIS

Scott Baver
Scott Baver
Senior Director, Pipeline Medical Affairs

APELLIS PHARMACEUTICALS

Sanaz Cardoza
Sanaz Cardoza
Medical Science Liaison

MALLINCKRODT PHARMACEUTICALS

Dan Davis
Dan Davis
Senior Director Oncology Medical Affairs

ELI LILLY

Dennis L Decktor, PhD MBA
Dennis L Decktor, PhD MBA
Medical Affairs Leader

FORMERLY J&J, REGENERON, NESTLE

Arindam Dey
Arindam Dey
Clinical Development & Medical Affairs Head

ALCON

Quinn Dinh
Quinn Dinh
Medical Affairs & Pipeline Launch Strategy Vice President, International

HORIZON THERAPEUTICS

Ashish Dugar
Ashish Dugar
Global Senior VP, Head of Medical Affairs

DYNE THERAPEUTICS

Anne Marie Greco
Anne Marie Greco
Global Director, Medical Affairs Early Portfolio

LEO PHARMA

Katie Luepke
Katie Luepke
Senior Medical Science Liaison

HERON THERAPEUTICS

Stephanie Macholtz
Stephanie Macholtz
Senior Director, Ethics & Compliance

HEALTHCARE COMPLIANCE COUNSEL

Dima Martini-Drew
Dima Martini-Drew
Senior Medical Director, TA Specialty

ASTELLAS

Barbara McGovern
Barbara McGovern
Vice President Medical Affairs

SERES THERAPEUTICS

Kristy Grimm Porter
Kristy Grimm Porter
Vice President, Global Medical Communications and Operations Global Medical

VERTEX PHARMACEUTICALS

Loredana Regep
Loredana Regep
Vice President, Medical & Regulatory Affairs

ROCHE

Oscar Segurado
Oscar Segurado
Chief Medical Officer

ASC THERAPEUTICS

Andrew Shim
Andrew Shim
Executive Director, Head of Global HEOR, Medical Affairs

TURNING POINT THERAPEUTICS

Diana Stefani-Hunyady
Diana Stefani-Hunyady
Senior Medical Director, Medical Affairs

TURNING POINT THERAPEUTICS

Megan Sutton
Megan Sutton
Medical Strategy-Cardiomyopathies, US Medical Affairs

BRISTOL MYERS SQUIBB

Wendy Wells
Wendy Wells
Director, Medical Affairs Training

APELLIS PHARMACEUTICALS

Top Reasons to Purchase

  1. Understanding the Value of Real-World Evidence Throughout the Development Stages to Support a Product’s Value
  2. Developing a Unique KOL Early Engagement Plan to Provide your Product a Critical Competitive Edge
  3. Involving a Qualified Medical Affairs Team from the Start to Execute a Designed Strategy and Achieve Medical Affairs Goals
  4. Implement a Well-Planned Strategy to Recruit, Engage and Manage your Medical Affairs Team Effectively.
  5. Improving Collaboration with R&D to Become a More Strategic Medical Affairs Partner

Who Should Purchase

Pharma, biotech, and medical device company professionals with responsibilities in:

  • Medical Science Liaison (MSL)
  • Medical Affairs
  • Early Stage Medical Affairs
  • KOL Relationship Management/ Development
  • Opinion/Thought Leader Relations
  • External Engagement
  • Chief Medical Officer
  • Commercial Operations
  • Medical and Professional Affairs/Strategy
  • Medical and Professional Education
  • Scientific/Medical Communication, Relations and Affairs
  • MSLs
  • Medical Communications
  • Scientific Affairs
  • Clinical Trials
  • Clinical Affairs
  • KOL Development
  • Scientific Advisor
  • Clinical Research
  • Medical Education
  • Clinical Investigation
  • Regulatory Affairs
  • Medical Science
  • Medical Information Specialist
  • Regulatory Affairs
  • R&D
  • Real World Evidence
SERVICE PROVIDERS
  • RWE Solution Providers
  • CROs
  • Consultancies